LEXINGTON, Mass., May 22, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Aldeyra. The underwriters purchased 122,500 additional shares from Aldeyra at the public offering price of $7.50 per share, less underwriting discounts and commissions.
Net proceeds to Aldeyra from the offering, including the sale of the additional shares, were approximately $19.9 million, after deducting underwriting discounts and commissions.
Cowen and Company, LLC and Canaccord Genuity Inc. acted as joint book-running managers and Janney Montgomery Scott LLC and Laidlaw & Company (UK) Ltd. acted as co-managers for the offering.
A registration statement relating to the offering was filed with the Securities and Exchange Commission on Form S-1, and declared effective on May 7, 2015. The offering was made by means of a prospectus. Copies of the prospectus related to the offering may be obtained from Cowen and Company, LLC on behalf of the underwriters, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjögren-Larsson Syndrome and noninfectious anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
CONTACT: Corporate Contact: Stephen Tulipano Aldeyra Therapeutics, Inc. Tel: +1 781-761-4904 Ext. 205 firstname.lastname@example.org Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009 email@example.comSource:Aldeyra Therapeutics